Elevation of histidine decarboxylase activity in the mandible of mice by Prevotella intermedia lipopolysaccharide and its augmentation by an aminobisphosphonate.
Lipopolysaccharide (LPS) produced by Gram-negative bacteria is an important cause of inflammation. Aminobisphosphonates are potent inhibitors of bone resorption but have inflammatory side-effects. Here, the effects of LPS from Prevotella intermedia (a prevalent Gram-negative bacterium both in periodontitis and endodontal infections) and alendronate (an aminobisphosphonate) on the activity of the histamine-forming enzyme, histidine decarboxylase (HDC), were examined in mouse mandible. Intravenous injection of P. intermedia LPS increased HDC activity in the mandible, maximal activity being induced within 3-6 h of the injection. The elevation of HDC activity was dependent on the dose of LPS, 10 microg/kg (0.25 microg/mouse) producing a significant elevation in enzyme activity. Intraperitoneal injection of alendronate (40 micromol/kg) also produced an increase in HDC activity. Moreover, the elevation of HDC activity induced by P. intermedia LPS was markedly augmented in mice given alendronate 3 days before the LPS injection. These results (i) suggest that P. intermedia LPS may stimulate the synthesis of histamine in the mandible and that the newly formed histamine may make at least some contribution to the development of inflammation (apical periodontitis and/or osteomyelitis); (ii) should encourage the clinical testing of antihistaminergic agents against inflammation; and (iii) confirm that care needs to be taken when administering aminobisphosphonates to patients.
Funayama
H
H
Department of Pediatric Dentistry, School of Dentistry, Tohoku University, Seiryo-machi, Aoba-ku Sendai 980, Japan.
Mayanagi
H
H
Takada
H
H
Endo
Y
Y
D019386:Alendronate / Q000494:pharmacology*; D000704:Analysis of Variance; D000818:Animals; D004357:Drug Synergism; D004789:Enzyme Activation / Q000187:drug effects; D006632:Histamine / Q000096:biosynthesis; D017442:Histamine Agonists / Q000494:pharmacology*; D006640:Histidine Decarboxylase / Q000378:metabolism*; D018836:Inflammation Mediators / Q000494:pharmacology*; D007274:Injections, Intraperitoneal; D007275:Injections, Intravenous; D008070:Lipopolysaccharides / Q000008:administration & dosage / Q000378:metabolism / Q000494:pharmacology*; D008334:Mandible / Q000201:enzymology; D051379:Mice; D008807:Mice, Inbred BALB C; D018713:Prevotella intermedia / Q000737:chemistry*
D017442:Histamine Agonists; D018836:Inflammation Mediators; D008070:Lipopolysaccharides; D006632:Histamine; D006640:Histidine Decarboxylase; D019386:Alendronate